Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
- FDA Orphan Drug Designation granted to avutometinib and defactinib for recurrent low-grade serous ovarian cancer.
- Ongoing Phase 3 trial (RAMP 301) evaluating the combination treatment.
- Targeting submission of rolling NDA for Accelerated Approval in the first half of 2024.
- Avutometinib and defactinib aim to address a high unmet medical need in LGSOC patients.
- LGSOC affects a younger patient population with significant mortality rates.
- Potential launch of the combination treatment in 2025.
- None.
The granting of Orphan Drug Designation (ODD) by the U.S. FDA to avutometinib, either as a monotherapy or in combination with defactinib, represents a significant endorsement for Verastem Oncology's commitment to address the unmet medical needs in recurrent low-grade serous ovarian cancer (LGSOC). The ODD status not only facilitates the development process by providing certain benefits, such as tax credits and market exclusivity upon approval, but it also underscores the urgency in finding effective treatments for this rare and challenging form of cancer.
From a clinical perspective, the focus on the RAS/MAPK Pathway alterations, which are prevalent in approximately 70% of LGSOC cases, is noteworthy. These genetic mutations are known to drive tumor growth and resistance to conventional chemotherapy, highlighting the potential of avutometinib and defactinib to provide a targeted therapeutic approach. The combination of a RAF/MEK clamp with a selective FAK inhibitor could offer a novel mechanism of action, potentially improving outcomes for a patient demographic that experiences high recurrence rates and limited treatment options.
Furthermore, the mention of a rolling New Drug Application (NDA) for Accelerated Approval indicates a proactive regulatory strategy that could expedite the availability of this treatment to patients. Given the high mortality rate and the severe pain and complications associated with LGSOC, accelerated access to new therapies could significantly impact patient quality of life and survival outcomes.
The Phase 3 RAMP 301 trial is a critical step in the clinical development pathway for avutometinib and defactinib. This trial's results will be pivotal in determining the efficacy and safety of the drug combination in a real-world patient population. The trial design and endpoints will likely focus on progression-free survival, overall survival and quality of life metrics, considering the disease's high recurrence rate and resistance to chemotherapy.
From a research analysis standpoint, the trial's success could set a precedent for similar targeted therapies in rare cancers. It is also important to note the potential economic implications for Verastem Oncology. A successful trial followed by FDA approval could lead to significant revenue generation, especially given the market exclusivity granted by the ODD. However, the cost of treatment and reimbursement strategies will be crucial factors in the commercial viability of the therapy.
Investors and stakeholders should closely monitor the trial's progress and interim data releases, as these will provide valuable insights into the treatment's potential market impact. Additionally, the company's preparation for a potential 2025 launch suggests confidence in the treatment's prospects, but it is essential to remain cautious until the trial data substantiates this optimism.
The announcement of the FDA's Orphan Drug Designation for Verastem Oncology's treatment options for LGSOC is likely to be well-received by investors, as it signals regulatory support and potential for market exclusivity. The designation could enhance investor confidence in the company's pipeline and its strategic focus on addressing rare cancers with high unmet medical needs.
Analyzing the financial implications, the tax benefits associated with the ODD can improve the company's fiscal efficiency and potentially attract investment for further research and development. Additionally, the market exclusivity period post-approval could protect the company's market share against competitors, contributing to a stronger long-term financial position.
Considering the estimated patient population numbers provided, the addressable market for the treatment appears substantial enough to drive significant revenue growth for Verastem Oncology upon successful approval and commercialization. However, the actual market penetration will depend on factors such as pricing, insurance coverage and the competitive landscape at the time of launch. Stakeholders should also consider the inherent risks of investing in biopharmaceutical companies, where drug development is costly, time-consuming and subject to regulatory uncertainties.
Recurrent low-grade serous ovarian cancer is a rare cancer with no FDA-approved treatments
Ongoing Phase 3 RAMP 301 trial is evaluating avutometinib and defactinib in recurrent low-grade serous ovarian cancer
On track to submit rolling NDA for Accelerated Approval in H1 2024
“The FDA Orphan Drug Designation for avutometinib alone or in combination with defactinib in low-grade serous ovarian cancer is an important step in recognizing this rare cancer as a distinct disease that currently has no FDA-approved treatments,” said Dan Paterson, president and chief executive officer of Verastem Oncology. “We are rapidly advancing the development program for avutometinib and defactinib in low-grade serous ovarian cancer with our ongoing Phase 3 clinical trial to deliver this new combination treatment to patients as quickly as possible. We remain on track to begin submission of an NDA to the FDA for Accelerated Approval of this combination in the first half of 2024 and preparing for a potential launch in 2025.”
Approximately
About the Avutometinib and Defactinib Combination
Avutometinib is a RAF/MEK clamp that induces inactive complexes of MEK with ARAF, BRAF and CRAF potentially creating a more complete and durable anti-tumor response through maximal RAS/MAPK pathway inhibition. In contrast to currently available MEK-only inhibitors, avutometinib blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK. This unique mechanism allows avutometinib to block MEK signaling without the compensatory activation of MEK that appears to limit the efficacy of other MEK-only inhibitors. The
Verastem Oncology is currently conducting clinical trials with its RAF/MEK clamp avutometinib in RAS/MAPK driven tumors as part of its (Raf And Mek Program). RAMP 301 (NCT06072781) is a Phase 3 confirmatory trial evaluating the combination of avutometinib and defactinib versus standard chemotherapy or hormonal therapy for the treatment of recurrent LGSOC. RAMP 201 (NCT04625270) is a Phase 2 registration-directed trial of avutometinib in combination with defactinib in patients with recurrent LGSOC and has completed enrollment in the dose optimization, expansion phase, and low-dose evaluation cohorts.
Verastem Oncology has established clinical collaborations with Amgen and Mirati to evaluate LUMAKRAS™ (sotorasib) and KRAZATI™ (adagrasib) in combination with avutometinib in KRAS G12C mutant NSCLC as part of the RAMP 203 (NCT05074810) and RAMP 204 (NCT05375994) trials, respectively. Supported by the “Therapeutic Accelerator Award” Verastem Oncology received from PanCAN, the Company is conducting RAMP 205 (NCT05669482), a Phase 1b/2 clinical trial evaluating avutometinib and defactinib with gemcitabine/nab-paclitaxel in patients with front-line metastatic pancreatic cancer.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.
Forward-Looking Statements Notice
This press release includes forward-looking statements about Verastem Oncology’s strategy, future plans and prospects, including statements related to the expected outcome and benefits of the Orphan Drug Designation for avutometinib in combination with defactinib in LGSOC, the potential clinical value of various of its clinical trials, the timing of commencing and completing trials, including topline data reports, interactions with regulators and the potential for and timing of commercialization of product candidates. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," “can,” “promising” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement.
Applicable risks and uncertainties include the risks and uncertainties, among other things, regarding: the success in the development and potential commercialization of our product candidates, including avutometinib in combination with other compounds, including defactinib, LUMAKRAS™ and others; the uncertainties inherent in research and development, such as negative or unexpected results of clinical trials, the occurrence or timing of applications for our product candidates that may be filed with regulatory authorities in any jurisdictions; whether and when regulatory authorities in any jurisdictions may approve any such applications that may be filed for our product candidates, and, if approved, whether our product candidates will be commercially successful in such jurisdictions; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the scope, timing, and outcome of any legal proceedings; decisions by regulatory authorities regarding trial design, labeling and other matters that could affect the timing, availability or commercial potential of our product candidates; whether preclinical testing of our product candidates and preliminary or interim data from clinical trials will be predictive of the results or success of ongoing or later clinical trials; that the timing, scope and rate of reimbursement for our product candidates is uncertain; that third-party payors (including government agencies) may not reimburse; that there may be competitive developments affecting our product candidates; that data may not be available when expected; that enrollment of clinical trials may take longer than expected; that our product candidates will cause adverse safety events and/or unexpected concerns may arise from additional data or analysis, or result in unmanageable safety profiles as compared to their levels of efficacy; that our product candidates may experience manufacturing or supply interruptions or failures; that any of our third party contract research organizations, contract manufacturing organizations, clinical sites, or contractors, among others, who we rely on fail to fully perform; that we face substantial competition, which may result in others developing or commercializing products before or more successfully than we do which could result in reduced market share or market potential for our product candidates; that we will be unable to successfully initiate or complete the clinical development and eventual commercialization of our product candidates; that the development and commercialization of our product candidates will take longer or cost more than planned, including as a result of conducting additional studies; that we may not have sufficient cash to fund our contemplated operations; that we may not attract and retain high quality personnel; that we or Chugai Pharmaceutical Co., Ltd. will fail to fully perform under the avutometinib license agreement; that our target market for our product candidates might be smaller than we are presently estimating; that Secura Bio, Inc. will fail to fully perform under the asset purchase agreement with Secura Bio, Inc., including in relation to milestone payments; that we will not see a return on investment on the payments we have and may continue to make pursuant to the collaboration and option agreement with GenFleet Therapeutics (
Other risks and uncertainties include those identified under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission (SEC) on March 14, 2023, and in any subsequent filings with the SEC. The forward-looking statements contained in this press release reflect Verastem Oncology’s views as of the date hereof, and the Company does not assume and specifically disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305616374/en/
For Investor and Media Inquiries:
Julissa Viana
Vice President, Corporate Communications and Investor Relations
investors@verastem.com or
media@verastem.com
Source: Verastem Oncology
